Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim clinical data a ...

Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partnered assets WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gener ...

Core Viewpoint - Acrivon Therapeutics is set to provide clinical data for its lead programs ACR-368 and ACR-2316 on January 8, 2026, highlighting advancements in precision medicine through its proprietary platform [1][4][7] Group 1: Company Overview - Acrivon Therapeutics is a clinical stage biotechnology company focused on discovering and developing precision medicines using its Generative Phosphoproteomics AP3 platform [3] - The AP3 platform enables unbiased interpretation and quantification of drug-regulated pathway activity levels in intact cells, generating terabytes of data for actionable insights [3] - Acrivon aims to overcome traditional drug discovery limitations by rapidly designing differentiated compounds and advancing them into clinical development [3] Group 2: Clinical Programs - ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, is currently in a Phase 2b trial for endometrial cancer and has received Fast Track designation from the FDA [4] - The ACR-2316 program, a WEE1/PKMYT1 inhibitor, is in Phase 1 trials, with initial clinical activity and dose proportionality observed in early cohorts [5][7] - Upcoming updates will include interim clinical data from the ACR-368 study and initial data from the ACR-2316 study, along with a new preclinical development candidate [7]

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, allowing for unbiased interpretation of compound-specific pathway activity levels, generating terabytes of data for actionable insights [2] - The AP3 platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, which enhance drug discovery beyond traditional methods [2] Clinical Programs - Acrivon's lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-368 has also received Breakthrough Device designation for its OncoSignature assay to identify suitable patients for treatment [3] - The second clinical asset, ACR-2316, is a WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data through a conference call and webcast in January 2026, including interim data from the Phase 2b study and the Phase 1 study of ACR-2316 [1][6]

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon Therapeutics utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, providing rapid and actionable insights from terabytes of proprietary data [2] - The platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, allowing for advanced drug discovery beyond traditional methods [2] Clinical Programs - The lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-2316, a second clinical stage asset, is a potent WEE1/PKMYT1 inhibitor showing promising early clinical activity and safety in a Phase 1 trial, with initial tumor shrinkage observed [4][6] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data via a conference call and webcast in January 2026, including interim data from ongoing trials and new preclinical candidates [1][6]

Core Insights - Acrivon Therapeutics is a clinical stage biotechnology company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables the interpretation and quantification of drug-regulated effects in intact cells [2][3] Company Overview - Acrivon utilizes its Generative Phosphoproteomics AP3 platform to develop precision medicines, allowing for unbiased interpretation of compound-specific pathway activity levels, generating terabytes of data for actionable insights [2] - The platform includes tools such as the AP3 Data Portal, AP3 Kinase Substrate Relationship Predictor, and AP3 Interactome, which enhance drug discovery beyond traditional methods [2] Clinical Programs - Acrivon's lead program, ACR-368 (prexasertib), is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [3] - ACR-2316, a second clinical stage asset, is a selective WEE1/PKMYT1 inhibitor showing promising preclinical results and is currently in a Phase 1 trial with initial clinical activity observed [4] Upcoming Updates - Acrivon plans to provide updates on ACR-368 and ACR-2316 clinical data in January 2026, including interim data from the Phase 2b study and initial results from the Phase 1 study of ACR-2316 [6]

Core Viewpoint - Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is highlighted as a promising investment opportunity due to its strong recent performance and significant upside potential, particularly driven by advancements in its clinical pipeline [1]. Group 1: Analyst Coverage and Price Target - H.C. Wainwright initiated coverage on Acrivon Therapeutics with a "Buy" rating and a price target of $19, reflecting a positive outlook based on the company's pipeline developments, especially the ACR-368 Phase 2b trial [2]. - The inclusion of a third cohort in the ACR-368 trial is expected to enhance enrollment and overall response rates, particularly for patients with less prior treatment, thereby improving market positioning [2]. Group 2: Financial Performance - In Q3 2025, Acrivon reported a net loss of $18.2 million, an improvement from a loss of $22.4 million in the same quarter the previous year [3]. - R&D expenses decreased from $18.9 million to $13.6 million, indicating a strategic focus on endometrial cancer [3]. - The company ended the quarter with cash reserves of $134.4 million, which is projected to fund operations into Q2 2027 [3]. Group 3: Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines utilizing its Generative Phosphoproteomics AP3 platform to create targeted treatments [4].

Core Insights - Acrivon Therapeutics is advancing its clinical pipeline, particularly focusing on ACR-368 for endometrial cancer, with a registrational-intent Phase 2b trial aimed at addressing unmet medical needs in relapsed patients [2][5] - The company is also preparing to disclose initial clinical data for ACR-2316 from its Phase 1 trial, which targets solid tumor types prioritized by its AP3 platform [1][2] - Acrivon's proprietary Generative Phosphoproteomics AP3 platform is enhancing drug discovery by enabling the design of differentiated compounds with desired pathway effects [1][6] Recent Highlights - ACR-368 is a CHK1 and CHK2 inhibitor currently in a multicenter Phase 2b trial for recurrent high-grade endometrial cancer [3][5] - ACR-2316, a WEE1/PKMYT1 inhibitor, has shown promising preclinical data, demonstrating tumor regression in xenograft models [4][5] - The AP3 platform's generative AI model, KaiSR, has been presented at conferences, showcasing its ability to predict pathway activity and support rational drug design [6] Financial Overview - For Q3 2025, Acrivon reported a net loss of $18.2 million, an improvement from a net loss of $22.4 million in Q3 2024 [8] - Research and development expenses decreased to $13.6 million in Q3 2025 from $18.9 million in the same period in 2024, reflecting a focus on endometrial cancer [9] - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $134.4 million, expected to fund operations into Q2 2027 [10] Upcoming Milestones - Acrivon plans to provide updates on the registrational-intent trial for ACR-368 and report initial clinical data for ACR-2316 in the second half of 2025 [13][14] - The company is also advancing a new potential first-in-class cell cycle drug discovery program towards candidate nomination in 2025 [13]

Core Insights - Acrivon Therapeutics is advancing its precision medicine development through its proprietary Generative Phosphoproteomics AP3 platform, which enables the assessment of drug effects on intracellular protein signaling networks for optimal drug design and precision medicine [1][4][5] - The company has reported favorable preclinical data for its lead asset ACR-2316, a novel WEE1/PKMYT1 inhibitor, demonstrating superior pathway effects compared to benchmark inhibitors [1][7] - Initial clinical data for ACR-2316 is expected to be reported later this year, with confirmed partial responses observed during the dose escalation phase of the trial [1][2][7] Presentation Details - Acrivon will present three posters at the AACR-NCI-EORTC International Conference, showcasing the AP3 platform and the preclinical activity of ACR-2316 [2][3] - The posters will cover topics such as the global pharmacodynamic effects of ACR-2316, the generative AI ensemble model (KaiSR), and the design of ACR-2316 for optimal pro-apoptotic pathway effects [3] Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines using its AP3 platform [4][5] - The company is also advancing ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2b trial for endometrial cancer, with Fast Track designation from the FDA [6][7] - Acrivon is leveraging its platform for developing additional pipeline programs, including ACR-2316, which has shown strong preclinical activity and is currently in a Phase 1 trial [7]